TY - JOUR
T1 - Epidemiology of Pulmonary and Extrapulmonary Nontuberculous Mycobacteria Infections at 4 US Emerging Infections Program Sites
T2 - A 6-Month Pilot
AU - Grigg, Cheri
AU - Jackson, Kelly A.
AU - Barter, Devra
AU - Czaja, Christopher A.
AU - Johnston, Helen
AU - Lynfield, Ruth
AU - Vagnone, Paula Snippes
AU - Tourdot, Laura
AU - Spina, Nancy
AU - Dumyati, Ghinwa
AU - Cassidy, P. Maureen
AU - Pierce, Rebecca
AU - Henkle, Emily
AU - Prevots, D. Rebecca
AU - Salfinger, Max
AU - Winthrop, Kevin L.
AU - Toney, Nadege Charles
AU - Magill, Shelley S.
N1 - Publisher Copyright:
© 2023 Published by Oxford University Press on behalf of Infectious Diseases Society of America.
PY - 2023/8/15
Y1 - 2023/8/15
N2 - Background: Nontuberculous mycobacteria (NTM) cause pulmonary (PNTM) and extrapulmonary (ENTM) disease. Infections are difficult to diagnose and treat, and exposures occur in healthcare and community settings. In the United States, NTM epidemiology has been described largely through analyses of microbiology data from health departments, electronic health records, and administrative data. We describe findings from a multisite pilot of active, laboratory-and population-based NTM surveillance. Methods: The Centers for Disease Control and Prevention's Emerging Infections Program conducted NTM surveillance at 4 sites (Colorado, 5 counties; Minnesota, 2 counties; New York, 2 counties; and Oregon, 3 counties [PNTM] and statewide [ENTM]) from 1 October 2019 through 31 March 2020. PNTM cases were defined using published microbiologic criteria. ENTM cases required NTM isolation from a nonpulmonary specimen, excluding stool and rectal swabs. Patient data were collected via medical record review. Results: Overall, 299 NTM cases were reported (PNTM: 231, 77%); Mycobacterium avium complex was the most common species group. Annualized prevalence was 7.5/100 000 population (PNTM: 6.1/100 000; ENTM: 1.4/100 000). Most patients had signs or symptoms in the 14 days before positive specimen collection (ENTM: 62, 91.2%; PNTM: 201, 87.0%). Of PNTM cases, 145 (62.8%) were female and 168 (72.7%) had underlying chronic lung disease. Among ENTM cases, 29 (42.6%) were female, 21 (30.9%) did not have documented underlying conditions, and 26 (38.2%) had infection at the site of a medical device or procedure. Conclusions: Active, population-based NTM surveillance will provide data for monitoring the burden of disease and characterize affected populations to inform interventions.
AB - Background: Nontuberculous mycobacteria (NTM) cause pulmonary (PNTM) and extrapulmonary (ENTM) disease. Infections are difficult to diagnose and treat, and exposures occur in healthcare and community settings. In the United States, NTM epidemiology has been described largely through analyses of microbiology data from health departments, electronic health records, and administrative data. We describe findings from a multisite pilot of active, laboratory-and population-based NTM surveillance. Methods: The Centers for Disease Control and Prevention's Emerging Infections Program conducted NTM surveillance at 4 sites (Colorado, 5 counties; Minnesota, 2 counties; New York, 2 counties; and Oregon, 3 counties [PNTM] and statewide [ENTM]) from 1 October 2019 through 31 March 2020. PNTM cases were defined using published microbiologic criteria. ENTM cases required NTM isolation from a nonpulmonary specimen, excluding stool and rectal swabs. Patient data were collected via medical record review. Results: Overall, 299 NTM cases were reported (PNTM: 231, 77%); Mycobacterium avium complex was the most common species group. Annualized prevalence was 7.5/100 000 population (PNTM: 6.1/100 000; ENTM: 1.4/100 000). Most patients had signs or symptoms in the 14 days before positive specimen collection (ENTM: 62, 91.2%; PNTM: 201, 87.0%). Of PNTM cases, 145 (62.8%) were female and 168 (72.7%) had underlying chronic lung disease. Among ENTM cases, 29 (42.6%) were female, 21 (30.9%) did not have documented underlying conditions, and 26 (38.2%) had infection at the site of a medical device or procedure. Conclusions: Active, population-based NTM surveillance will provide data for monitoring the burden of disease and characterize affected populations to inform interventions.
KW - epidemiology
KW - nontuberculous mycobacteria
KW - surveillance
UR - http://www.scopus.com/inward/record.url?scp=85164948191&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85164948191&partnerID=8YFLogxK
U2 - 10.1093/cid/ciad214
DO - 10.1093/cid/ciad214
M3 - Article
C2 - 37083882
AN - SCOPUS:85164948191
SN - 1058-4838
VL - 77
SP - 629
EP - 637
JO - Clinical Infectious Diseases
JF - Clinical Infectious Diseases
IS - 4
ER -